About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Ndor1+
wild type
MGI:3049068
Summary 23 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Zfp574em3Btlr/Zfp574em3Btlr
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr MGI:7790547
cn2
 		Zfp574em3Btlr/Zfp574em3Btlr
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Tg(IghMyc)22Bri/0 		B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr Tg(IghMyc)22Bri MGI:7790549
cn3
 		Stk26tm1.1Zzh/Stk26tm1.1Zzh
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL MGI:6695866
cn4
 		Stk26tm1.1Zzh/Stk26+
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL MGI:6695867
cn5
 		Adcy3tm2.1Drs/Adcy3tm2.1Drs
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129 * 129X1/SvJ * C57BL/6 MGI:7260162
cn6
 		Leprtm1Rck/Leprtm1Rck
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129 * C57BL/6 MGI:7782473
cn7
 		Eif4btm1.1Smoc/Eif4btm1.1Smoc
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129 * C57BL/6 MGI:6790428
cn8
 		Esco2tm1.1Ge/Esco2tm1.1Ge
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S2/SvPas * C57BL/6 * SJL MGI:6828779
cn9
 		Esco1tm1.1Ge/Esco1tm1.1Ge
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S2/SvPas * C57BL/6 * SJL MGI:6828777
cn10
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Y 		involves: 129S6/SvEvTac * C57BL/6NCrl MGI:6490363
cn11
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Stag2tm1.1Alos 		involves: 129S6/SvEvTac * C57BL/6NCrl MGI:6490362
cn12
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rpl11tm1.1Srn/Rpl11+ 		involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1 MGI:6510523
cn13
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rpl11tm1.1Srn/Rpl11tm1.1Srn 		involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1 MGI:6510297
cn14
 		Rad51tm1Csha/Rad51tm1Csha
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/Sv * C57BL/6J MGI:7311703
cn15
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rragatm2Dmsa/Rragatm2Dmsa 		involves: 129S/SvEv * 129S4/SvJae * C57BL/6 MGI:6236293
cn16
 		Gm30731tm1.1Dalm/Gm30731tm1.1Dalm
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/SvEv * C57BL/6 MGI:6385157
cn17
 		Dcp2tm1Smoc/Dcp2tm1Smoc
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/SvEv * C57BL/6 MGI:6459915
cn18
 		Lcn6tm1.1Ylzh/Lcn6tm1.1Ylzh
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/SvEv * C57BL/6 MGI:6121436
cn19
 		Dido1tm3Cmar/Dido1tm3.1Cmar
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/SvEv * C57BL/6 MGI:7343747
cn20
 		Armcx3tm1.1Eso/Y
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ 		involves: 129S/SvEv * C57BL/6 MGI:7612206
cn21
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3+ 		involves: 129S/SvEv * C57BL/6 * C57BL/6N MGI:6276274
cn22
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3tm1c(EUCOMM)Wtsi 		involves: 129S/SvEv * C57BL/6 * C57BL/6N MGI:6276277
cx23
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Trp53tm1Brd/Trp53tm1Brd 		involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N MGI:6403623


Genotype
MGI:7790547
cn1
Allelic
Composition		 Zfp574em3Btlr/Zfp574em3Btlr
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Zfp574em3Btlr mutation (0 available); any Zfp574 mutation (27 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
macrocytic anemia ( J:354285 )
• tamoxifen-treated mice exhibit macrocytic anemia
decreased B cell number ( J:354285 )
• transplantation of a 1:1 mixture of mutant and congenic wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen 12 weeks after bone marrow transplantation exhibit 40.3% elimination of mutant nonmalignant B cells
pancytopenia ( J:354285 )
• tamoxifen-treated mice exhibit pancytopenia with macrocytic anemia
abnormal hematopoietic stem cell morphology ( J:354285 )
• transplantation of a 1:1 mixture of mutant and congenic wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen at 12 weeks posttransplant show rapid deletion of all hematopoietic stem and progenitor cell (HSPC) populations derived specifically from mutant bone marrow; progenitor cell populations are more severely affected that hematopoietic stem cells

immune system
decreased B cell number ( J:354285 )
• transplantation of a 1:1 mixture of mutant and congenic wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen 12 weeks after bone marrow transplantation exhibit 40.3% elimination of mutant nonmalignant B cells




Genotype
MGI:7790549
cn2
Allelic
Composition		 Zfp574em3Btlr/Zfp574em3Btlr
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Tg(IghMyc)22Bri/0
Genetic
Background		 B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb Zfp574em3Btlr Tg(IghMyc)22Bri
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Tg(IghMyc)22Bri mutation (1 available)
Zfp574em3Btlr mutation (0 available); any Zfp574 mutation (27 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
decreased B cell number ( J:354285 )
• transplantation of a 1:1 mixture of mutant and wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen 12 weeks after bone marrow transplantation exhibit more rapid elimination of leukemic B cells than nonmalignant Zfp574em3Btlr/Zfp574em3Btlr Ndor1Tg(UBC-cre/ERT2)1Ejb mice; up to 79.3% of established leukemic B cells are eliminated after the first dose of tamoxifen and 91.9% of leukemic B cells are eliminated after a second tamoxifen dose

immune system
decreased B cell number ( J:354285 )
• transplantation of a 1:1 mixture of mutant and wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen 12 weeks after bone marrow transplantation exhibit more rapid elimination of leukemic B cells than nonmalignant Zfp574em3Btlr/Zfp574em3Btlr Ndor1Tg(UBC-cre/ERT2)1Ejb mice; up to 79.3% of established leukemic B cells are eliminated after the first dose of tamoxifen and 91.9% of leukemic B cells are eliminated after a second tamoxifen dose

neoplasm
decreased leukemia incidence ( J:354285 )
• transplantation of a 1:1 mixture of mutant and wild-type bone marrow cells into lethally irradiated CD45.1 recipients that were injected with tamoxifen 12 weeks after bone marrow transplantation exhibit more rapid elimination of leukemic B cells than nonmalignant Zfp574em3Btlr/Zfp574em3Btlr Ndor1Tg(UBC-cre/ERT2)1Ejb mice; up to 79.3% of established leukemic B cells are eliminated after the first dose of tamoxifen and 91.9% of leukemic B cells are eliminated after a second tamoxifen dose




Genotype
MGI:6695866
cn3
Allelic
Composition		 Stk26tm1.1Zzh/Stk26tm1.1Zzh
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Stk26tm1.1Zzh mutation (0 available); any Stk26 mutation (11 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased incidence of tumors by chemical induction ( J:289548 )
• tamoxifen-induced 8-week-old mice treated with the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) show an increase in the numbers of palpable gastric tumors compared to wild-type mice

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:289548 )
• tamoxifen-induced 8-week-old mice treated with the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) show an increase in the numbers of palpable gastric tumors compared to wild-type mice




Genotype
MGI:6695867
cn4
Allelic
Composition		 Stk26tm1.1Zzh/Stk26+
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Stk26tm1.1Zzh mutation (0 available); any Stk26 mutation (11 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased incidence of tumors by chemical induction ( J:289548 )
• tamoxifen-induced 8-week-old mice treated with the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) show an increase in the numbers of palpable gastric tumors compared to wild-type mice

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:289548 )
• tamoxifen-induced 8-week-old mice treated with the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) show an increase in the numbers of palpable gastric tumors compared to wild-type mice




Genotype
MGI:7260162
cn5
Allelic
Composition		 Adcy3tm2.1Drs/Adcy3tm2.1Drs
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129 * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Adcy3tm2.1Drs mutation (0 available); any Adcy3 mutation (43 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
behavior/neurological
abnormal response to new environment ( J:281839 )
• tamoxifen-administered adults show a slightly longer latency to feed than controls in the novelty-suppressed feeding test
behavioral despair ( J:281839 )
• adult mice administered tamoxifen orally show longer periods of immobility in the tail suspension test and the force swim test
decreased grooming behavior ( J:281839 )
• tamoxifen-administered adults exhibit a poor coat state, suggesting decreased grooming
hypoactivity ( J:281839 )
• tamoxifen-administered adults are less active than controls in their home cage during the night
abnormal circadian sleep/wake cycle ( J:281839 )
• tamoxifen-administered adults show altered sleep; the sleep-wake cycle is not very rhythmic
abnormal non-rapid eye movement sleep pattern ( J:281839 )
• mice have more NREM sleep in nighttime and less NREM sleep in daytime than controls
abnormal nest building behavior ( J:281839 )
• tamoxifen-administered adults perform poorly in nest building

homeostasis/metabolism
increased circulating corticosterone level ( J:281839 )
• tamoxifen-administered adults exhibit a higher level of corticosterone




Genotype
MGI:7782473
cn6
Allelic
Composition		 Leprtm1Rck/Leprtm1Rck
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Leprtm1Rck mutation (1 available); any Lepr mutation (124 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
growth/size/body
obese ( J:344866 )
• mice gain approximately 17-19 grams over 4 weeks after tamoxifen treatment

homeostasis/metabolism
increased circulating leptin level ( J:344866 )
• tamoxifen-treated mice develop hyperleptinemia
• hyperleptinemia in tamoxifen-treated mice is resistant to auranofin treatment
decreased physiological sensitivity to xenobiotic ( J:344866 )
• tamoxifen-treated mice lack metabolic responses to the drug auranofin, with no effect on hyperleptinemia, food intake, respiratory exchange ratio, activity, insulin and glucose tolerance, fasting insulin levels, or fatty liver and auranofin treatment does not increase fasting serum free fatty acids as in wild-type mice
• tamoxifen-treated mice lack the anti-inflammatory responses to auranofin in epididymal white adipose tissue (eWAT) that are seen in wild-type mice and auranofin treatment does not increase eWAT oxygen consumption rates




Genotype
MGI:6790428
cn7
Allelic
Composition		 Eif4btm1.1Smoc/Eif4btm1.1Smoc
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eif4btm1.1Smoc mutation (0 available); any Eif4b mutation (47 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality ( J:311140 )
• tamoxifen-treated mice infected with influenza virus lose more weight and die within 8 days compared to controls in which 30% survive at the end of the experiments
premature death ( J:311140 )
• majority of mice treated with tamoxifen at 10-12 weeks of age for 5 days die within 10 days

growth/size/body
weight loss ( J:311140 )
• mice show more body weight loss than controls after the first injection of tamoxifen

behavior/neurological
decreased food intake ( J:311140 )
• tamoxifen-treated mice exhibit loss of appetite
decreased locomotor activity ( J:311140 )
• tamoxifen-treated mice exhibit loss of motility

digestive/alimentary system
increased susceptibility to induced colitis ( J:311140 )
• tamoxifen-treated mice exhibit more severe dextran sulfate sodium (DSS)-induced colonic injury, with more weight loss, shorter colon length and more severe inflammation

endocrine/exocrine glands
small thymus ( J:311140 )
• thymus is smaller in tamoxifen-treated mice

hematopoietic system
small thymus ( J:311140 )
• thymus is smaller in tamoxifen-treated mice
increased neutrophil cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza virus exhibit increased number of neutrophils or alveolar macrophages in the lungs
increased macrophage cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza virus exhibit increased number of alveolar macrophages in the lungs
decreased leukocyte cell number ( J:311140 )
• tamoxifen treated mice show a decrease in the number of white blood cells
• however, no effect on numbers of red blood cells or platelets is seen
decreased lymphocyte cell number ( J:311140 )
• total number and the percentage of lymphocytes is decreased in peripheral blood cells of tamoxifen-treated mice
• tamoxifen-treated mice show a decrease in lymphocytes in the spleen and thymus
• percentage of CD4+ and CD8+ lymphocytes is reduced in lungs of tamoxifen-treated influenza A virus infected mice
decreased NK cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza A virus show decreased natural killer cells in the lungs compared to controls
• tamoxifen-treated mice infected with influenza A show decreased number of IFN-gamma+ and CD107a+ natural killer cells indicating impaired infiltration of natural killer cells and their function in the lung in response to influenza A infection
small spleen ( J:311140 )
• spleen is smaller in tamoxifen-treated mice

immune system
increased susceptibility to induced colitis ( J:311140 )
• tamoxifen-treated mice exhibit more severe dextran sulfate sodium (DSS)-induced colonic injury, with more weight loss, shorter colon length and more severe inflammation
small thymus ( J:311140 )
• thymus is smaller in tamoxifen-treated mice
increased neutrophil cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza virus exhibit increased number of neutrophils or alveolar macrophages in the lungs
increased macrophage cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza virus exhibit increased number of alveolar macrophages in the lungs
decreased leukocyte cell number ( J:311140 )
• tamoxifen treated mice show a decrease in the number of white blood cells
• however, no effect on numbers of red blood cells or platelets is seen
decreased lymphocyte cell number ( J:311140 )
• total number and the percentage of lymphocytes is decreased in peripheral blood cells of tamoxifen-treated mice
• tamoxifen-treated mice show a decrease in lymphocytes in the spleen and thymus
• percentage of CD4+ and CD8+ lymphocytes is reduced in lungs of tamoxifen-treated influenza A virus infected mice
decreased NK cell number ( J:311140 )
• tamoxifen-treated mice infected with influenza A virus show decreased natural killer cells in the lungs compared to controls
• tamoxifen-treated mice infected with influenza A show decreased number of IFN-gamma+ and CD107a+ natural killer cells indicating impaired infiltration of natural killer cells and their function in the lung in response to influenza A infection
small spleen ( J:311140 )
• spleen is smaller in tamoxifen-treated mice
lung inflammation ( J:311140 )
• tamoxifen-treated mice infected with pseudorabies virus show increased percentages of neutrophils, alveolar macrophages and monocytes in the lungs, indicating enhanced pulmonary inflammation in response to viral infection
increased susceptibility to Orthomyxoviridae infection ( J:311140 )
• tamoxifen-treated mice show increased susceptibility to influenza A virus, showing a higher degree of acute lung injury, more severe inflammation and inflammatory cell infiltration in the lungs, higher protein levels of viral NP in the lungs and increased viral titers in the lungs compared to controls
increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality ( J:311140 )
• tamoxifen-treated mice infected with influenza virus lose more weight and die within 8 days compared to controls in which 30% survive at the end of the experiments

integument
matted coat ( J:311140 )
• tamoxifen-treated mice exhibit matted hairs

respiratory system
lung inflammation ( J:311140 )
• tamoxifen-treated mice infected with pseudorabies virus show increased percentages of neutrophils, alveolar macrophages and monocytes in the lungs, indicating enhanced pulmonary inflammation in response to viral infection




Genotype
MGI:6828779
cn8
Allelic
Composition		 Esco2tm1.1Ge/Esco2tm1.1Ge
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S2/SvPas * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Esco2tm1.1Ge mutation (1 available); any Esco2 mutation (35 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
abnormal mitosis ( J:296958 )
• tamoxifen-treated mouse embryonic fibroblasts arrest in S-phase




Genotype
MGI:6828777
cn9
Allelic
Composition		 Esco1tm1.1Ge/Esco1tm1.1Ge
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S2/SvPas * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Esco1tm1.1Ge mutation (0 available); any Esco1 mutation (50 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
abnormal mitosis ( J:296958 )
• tamoxifen-treated mouse embryonic fibroblasts arrest in G1




Genotype
MGI:6490363
cn10
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Y
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6NCrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Stag2tm1.1Alos mutation (0 available); any Stag2 mutation (14 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:298088 )
• 4 weeks after initiation of tamoxifen treatment

cellular
abnormal mitosis ( J:298088 )
• tamoxifen-treated mouse embryonic fibroblasts exhibit increased chromosome adhesion and mis-segregation compared with control cells
increased fibroblast apoptosis ( J:298088 )
• increased caspase-3-positive cells in tamoxifen-treated mouse embryonic fibroblasts
cellular necrosis ( J:298088 )
• 8 week old tamoxifen-treated mice exhibit increased intestinal erosion and necrosis compared with wild-type mice
abnormal enterocyte proliferation ( J:298088 )
• reduced in intestinal crypts of tamoxifen-treated mice indicating reduced cellular renewal
decreased fibroblast proliferation ( J:298088 )
• increased doubling time in tamoxifen-treated mouse embryonic fibroblasts

digestive/alimentary system
abnormal enterocyte proliferation ( J:298088 )
• reduced in intestinal crypts of tamoxifen-treated mice indicating reduced cellular renewal
abnormal intestine morphology ( J:298088 )
• 8 week old tamoxifen-treated mice exhibit increased intestinal erosion and necrosis compared with wild-type mice

growth/size/body
decreased body weight ( J:298088 )
• in tamoxifen-treated mice

hematopoietic system
hematopoietic system phenotype ( J:298088 )
N
• tamoxifen-treated mice exhibit normal adult hematopoiesis
abnormal hematopoietic stem cell physiology ( J:298088 )
• enhanced self-renewal in cells from tamoxifen-treated mice

neoplasm
neoplasm ( J:298088 )
N
• tamoxifen-treated mice do not exhibit increased spontaneous tumors




Genotype
MGI:6490362
cn11
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Stag2tm1.1Alos/Stag2tm1.1Alos
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6NCrl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Stag2tm1.1Alos mutation (0 available); any Stag2 mutation (14 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:298088 )
• 4 weeks after initiation of tamoxifen treatment

cellular
abnormal mitosis ( J:298088 )
• tamoxifen-treated mouse embryonic fibroblasts exhibit increased chromosome adhesion and mis-segregation compared with control cells
increased fibroblast apoptosis ( J:298088 )
• increased caspase-3-positive cells in tamoxifen-treated mouse embryonic fibroblasts
cellular necrosis ( J:298088 )
• 8 week old tamoxifen-treated mice exhibit increased intestinal erosion and necrosis compared with wild-type mice
abnormal enterocyte proliferation ( J:298088 )
• reduced in intestinal crypts of tamoxifen-treated mice indicating reduced cellular renewal
decreased fibroblast proliferation ( J:298088 )
• increased doubling time in tamoxifen-treated mouse embryonic fibroblasts

digestive/alimentary system
abnormal enterocyte proliferation ( J:298088 )
• reduced in intestinal crypts of tamoxifen-treated mice indicating reduced cellular renewal
abnormal intestine morphology ( J:298088 )
• 8 week old tamoxifen-treated mice exhibit increased intestinal erosion and necrosis compared with wild-type mice

growth/size/body
decreased body weight ( J:298088 )
• in tamoxifen-treated mice

hematopoietic system
hematopoietic system phenotype ( J:298088 )
• tamoxifen-treated mice exhibit normal adult hematopoiesis
abnormal hematopoietic stem cell physiology ( J:298088 )
• enhanced self-renewal in cells from tamoxifen-treated mice

neoplasm
neoplasm ( J:298088 )
• tamoxifen-treated mice do not exhibit increased spontaneous tumors




Genotype
MGI:6510523
cn12
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rpl11tm1.1Srn/Rpl11+
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rpl11tm1.1Srn mutation (1 available); any Rpl11 mutation (16 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal erythropoiesis ( J:292575 )
• tamoxifen-treated mice show defective erythropoiesis, with bone marrow showing an increase in the percentage of primitive progenitors and proerythroblasts (RI cells) and a decrease in the more matured stages (RIII, RIV, and RV cells)
• fetal livers from tamoxifen-treated pregnant mothers show an increase in the percentage of primitive progenitors and proerythroblasts (RI cells) and a decrease in the more matured stages (RIII, RIV, and RV cells)
• bone marrow of transplanted SCID mice show an increase in the percentage of primitive progenitors and proerythroblasts (RI cells) and a decrease in the more matured stages (RIII, RIV, and RV)
• fetal liver erythroid progenitors from tamoxifen-treated pregnant mothers show lower proliferation (increase in cells in G1 and a tendency of decrease in cells in S phase)
anemia ( J:292575 )
• tamoxifen-treated mice develop anemia
• mice irradiated with a single dose of gamma-radiation and treated with tamoxifen 1 week later develop anemia
abnormal proerythroblast morphology ( J:292575 )
• bone marrow of tamoxifen-treated mice shows an increase in the percentage of primitive progenitors and proerythroblasts (RI cells)
• bone marrow of transplanted SCID mice show an increase in the percentage of primitive progenitors and proerythroblasts (RI cells)
decreased erythroblast number ( J:292575 )
• mutant bone marrow transplanted SCID mice show a severe decrease in erythroblasts
• however, the bone marrow is histologically normocellular and has normal ratios of hematopoietic stem cells and progenitor cells
• bone marrow shows a decrease in the number of erythroblasts in tamoxifen-treated mice
decreased erythrocyte cell number ( J:292575 )
• mice fed a tamoxifen diet starting at 1.5-2 months of age exhibit lower red blood cell levels which becomes more pronounced with age
• mutant bone marrow transplanted SCID mice show reduced red blood cell levels over time
decreased hemoglobin content ( J:292575 )
• mutant bone marrow transplanted SCID mice show decreased hemoglobin levels over time
macrocytosis ( J:292575 )
• tamoxifen-treated mice exhibit macrocytosis which becomes more pronounced with age

homeostasis/metabolism
increased mortality induced by gamma-irradiation ( J:292575 )
• gamma-irradiated mice treated with tamoxifen die earlier than controls

mortality/aging
increased mortality induced by gamma-irradiation ( J:292575 )
• gamma-irradiated mice treated with tamoxifen die earlier than controls

neoplasm
increased incidence of tumors by ionizing radiation induction ( J:292575 )
• gamma-irradiated mice treated with tamoxifen develop lymphomas, particularly in the thymus

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
Diamond-Blackfan anemia 7 DOID:0111878 OMIM:612562
 J:292575




Genotype
MGI:6510297
cn13
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rpl11tm1.1Srn/Rpl11tm1.1Srn
Genetic
Background		 involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rpl11tm1.1Srn mutation (1 available); any Rpl11 mutation (16 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:292575 )
• mice treated with tamoxifen starting at 1.5 months of age show lethality, with no mice surviving beyond 8 weeks of tamoxifen treatment

digestive/alimentary system
abnormal intestine morphology ( J:292575 )
• tamoxifen-treated mice show intestinal atrophy

hematopoietic system
anemia ( J:292575 )
• at time of death, tamoxifen-treated mice show signs of developing anemia, including a pronounced decrease in bone marrow erythroblasts and an accumulation of hemosiderin in the spleen and iron in the liver
abnormal bone marrow cell morphology/development ( J:292575 )
• tamoxifen-treated mice show bone marrow aplasia
decreased erythroblast number ( J:292575 )
• tamoxifen-treated mice show a decrease in bone marrow erythroblasts at time of death

homeostasis/metabolism
increased liver iron level ( J:292575 )
• tamoxifen-treated mice show an accumulation of iron in the liver at time of death

liver/biliary system
increased liver iron level ( J:292575 )
• tamoxifen-treated mice show an accumulation of iron in the liver at time of death




Genotype
MGI:7311703
cn14
Allelic
Composition		 Rad51tm1Csha/Rad51tm1Csha
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/Sv * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rad51tm1Csha mutation (0 available); any Rad51 mutation (29 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
decreased male germ cell number ( J:324159 )
• at P70, no PLZF+ spermatogonial stem cells (SSCs) are detected in the seminiferous tubules of tamoxifen-treated mice
• at P14, no pachytene spermatocytes are detected in the tubules of tamoxifen-treated mice
increased male germ cell apoptosis ( J:324159 )
• at P14 and P70, the number of TUNEL+ apoptotic spermatocytes in the seminiferous tubules of tamoxifen-treated mice is significantly higher than in control males
small testis ( J:324159 )
• at P70, tamoxifen-treated mice show a significantly smaller testis size than control males
decreased testis weight ( J:324159 )
• at P70, testis weight in tamoxifen-treated mice is 80% of that in control males
abnormal spermatogenesis ( J:324159 )
• tamoxifen-treated males exhibit early spermatogenic cells loss and apoptosis
abnormal spermatocyte morphology ( J:324159 )
• at P14, no pachytene spermatocytes are detected in the seminiferous tubules of tamoxifen-treated mice
• at P70, chromosome spreads from tamoxifen-treated testes show a significant decrease in leptotene, zygotene and pachytene spermatocytes with a concomitant increase in diplotene and metaphase I cells relative to control testes
• at P70, % of pachytene spermatocytes is significantly lower than in control testes (12.57% versus 41.37%) whereas % of diplotene spermatocytes is significantly increased (82.74% versus 48.83%)
abnormal male meiosis ( J:324159 )
• at P14, no meiotic cells are found in the testes of tamoxifen-treated mice; only mitotic cells are observed
• no SYCP3+ or gammaH2AX+ cells are observed in the seminiferous tubules of tamoxifen-treated mice at P14
• at P70, chromosome spreads from tamoxifen-treated testes show meiosis defects, including a significant reduction in zygotene and pachytene spermatocytes, defective double-strand DNA repair, and a significant decrease in MLH1 foci in pachytene spermatocytes indicating reduced crossover formation

cellular
abnormal spermatocyte morphology ( J:324159 )
• at P14, no pachytene spermatocytes are detected in the seminiferous tubules of tamoxifen-treated mice
• at P70, chromosome spreads from tamoxifen-treated testes show a significant decrease in leptotene, zygotene and pachytene spermatocytes with a concomitant increase in diplotene and metaphase I cells relative to control testes
• at P70, % of pachytene spermatocytes is significantly lower than in control testes (12.57% versus 41.37%) whereas % of diplotene spermatocytes is significantly increased (82.74% versus 48.83%)
decreased male germ cell number ( J:324159 )
• at P70, no PLZF+ spermatogonial stem cells (SSCs) are detected in the seminiferous tubules of tamoxifen-treated mice
• at P14, no pachytene spermatocytes are detected in the tubules of tamoxifen-treated mice
abnormal male meiosis ( J:324159 )
• at P14, no meiotic cells are found in the testes of tamoxifen-treated mice; only mitotic cells are observed
• no SYCP3+ or gammaH2AX+ cells are observed in the seminiferous tubules of tamoxifen-treated mice at P14
• at P70, chromosome spreads from tamoxifen-treated testes show meiosis defects, including a significant reduction in zygotene and pachytene spermatocytes, defective double-strand DNA repair, and a significant decrease in MLH1 foci in pachytene spermatocytes indicating reduced crossover formation
increased male germ cell apoptosis ( J:324159 )
• at P14 and P70, the number of TUNEL+ apoptotic spermatocytes in the seminiferous tubules of tamoxifen-treated mice is significantly higher than in control males
abnormal double-strand DNA break repair ( J:324159 )
• at P70, chromosome spreads from tamoxifen-treated testes show abnormal accumulation of gammaH2AX foci on the axes of autosomal chromosomes as well as a significant increase of DMC1 foci in pachytene spermatocytes, indicating an increased incidence of unrepaired DNA breaks

homeostasis/metabolism
abnormal double-strand DNA break repair ( J:324159 )
• at P70, chromosome spreads from tamoxifen-treated testes show abnormal accumulation of gammaH2AX foci on the axes of autosomal chromosomes as well as a significant increase of DMC1 foci in pachytene spermatocytes, indicating an increased incidence of unrepaired DNA breaks

endocrine/exocrine glands
small testis ( J:324159 )
• at P70, tamoxifen-treated mice show a significantly smaller testis size than control males
decreased testis weight ( J:324159 )
• at P70, testis weight in tamoxifen-treated mice is 80% of that in control males




Genotype
MGI:6236293
cn15
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rragatm2Dmsa/Rragatm2Dmsa
Genetic
Background		 involves: 129S/SvEv * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rragatm2Dmsa mutation (0 available); any Rraga mutation (17 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:213516 )
• over 50% of mice die within 2-3 weeks after the start of tamoxifen treatment

digestive/alimentary system
abnormal intestine apoptosis ( J:213516 )
• frequent apoptotic figures in small intestine after tamoxifen treatment
• small intestinal atrophy

growth/size/body
weight loss ( J:213516 )
• transiently lose about 20% of body weight within 1 week of tamoxifen injection
enlarged spleen ( J:213516 )

immune system
myeloid hyperplasia ( J:213516 )
• expansion of myeloid cells spreads to peripheral tissues in mice that survive more than 2 weeks after tamoxifen treatment
decreased B cell number ( J:213516 )
• expansion of monocytes is accompanied by profound reduction in B lymphocytes and/or their progenitors
increased monocyte cell number ( J:213516 )
• accumulation of monocytes in the spleen and bone marrow

neoplasm
increased lymphoma incidence ( J:213516 )
• expansion of myeloid cells is histopathologically reminiscent of histiocytic sarcoma

cellular
abnormal intestine apoptosis ( J:213516 )
• frequent apoptotic figures in small intestine after tamoxifen treatment
• small intestinal atrophy
increased apoptosis ( J:213516 )
• frequent apoptotic figures in small intestine after tamoxifen treatment

hematopoietic system
myeloid hyperplasia ( J:213516 )
• expansion of myeloid cells spreads to peripheral tissues in mice that survive more than 2 weeks after tamoxifen treatment
decreased B cell number ( J:213516 )
• expansion of monocytes is accompanied by profound reduction in B lymphocytes and/or their progenitors
increased monocyte cell number ( J:213516 )
• accumulation of monocytes in the spleen and bone marrow




Genotype
MGI:6385157
cn16
Allelic
Composition		 Gm30731tm1.1Dalm/Gm30731tm1.1Dalm
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gm30731tm1.1Dalm mutation (0 available); any Gm30731 mutation (0 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
nervous system
abnormal neuronal stem cell physiology ( J:281278 )
• increased neurogenesis of ventricular-subventricular zone neural stem cell cultures treated with tamoxifen with 6-fold more neurons




Genotype
MGI:6459915
cn17
Allelic
Composition		 Dcp2tm1Smoc/Dcp2tm1Smoc
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dcp2tm1Smoc mutation (0 available); any Dcp2 mutation (39 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
decreased male germ cell number ( J:292283 )
• progressive loss with only a few elongated spermatids in tamoxifen-treated mice
increased male germ cell apoptosis ( J:292283 )
• in tamoxifen-treated mice
asthenozoospermia ( J:292283 )
• in tamoxifen-treated mice
decreased testis weight ( J:292283 )
• in tamoxifen-treated mice
male infertility ( J:292283 )
• in tamoxifen-treated mice

homeostasis/metabolism
decreased circulating testosterone level ( J:292283 )
• in tamoxifen-treated mice

cellular
decreased male germ cell number ( J:292283 )
• progressive loss with only a few elongated spermatids in tamoxifen-treated mice
increased male germ cell apoptosis ( J:292283 )
• in tamoxifen-treated mice
asthenozoospermia ( J:292283 )
• in tamoxifen-treated mice

endocrine/exocrine glands
decreased testis weight ( J:292283 )
• in tamoxifen-treated mice




Genotype
MGI:6121436
cn18
Allelic
Composition		 Lcn6tm1.1Ylzh/Lcn6tm1.1Ylzh
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lcn6tm1.1Ylzh mutation (0 available); any Lcn6 mutation (21 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
reproductive system phenotype ( J:256079 )
N
• after tamoxifen treatment fertility was not impaired and sperm fertilization ability, motility, and capacitation were similar to controls
abnormal sperm physiology ( J:256079 )
• sperm from tamoxifen treated males show elevated intracellular calcium levels
premature acrosome reaction ( J:256079 )
• sperm from tamoxifen treated males show enhanced spontaneous acrosome reaction frequencies when non-capacitated or capacitated for 1 h

homeostasis/metabolism
abnormal calcium ion homeostasis ( J:256079 )
• sperm from tamoxifen treated males show elevated intracellular calcium levels




Genotype
MGI:7343747
cn19
Allelic
Composition		 Dido1tm3Cmar/Dido1tm3.1Cmar
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dido1tm3.1Cmar mutation (0 available); any Dido1 mutation (186 available)
Dido1tm3Cmar mutation (1 available); any Dido1 mutation (186 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
small testis ( J:328215 )
• after 35 days of tamoxifen treatment
decreased testis weight ( J:328215 )
• after 35 days of tamoxifen treatment
testis degeneration ( J:328215 )
• with partial collapse of seminiferous tubules and defective germ line maturation in tamoxifen-treated mice
male infertility ( J:328215 )
• 4 of 7 tamoxifen-treated male mice are infertile compared with 1 of 5 wild-type mice

behavior/neurological
ataxia ( J:328215 )
• progressively increasing with age in tamoxifen-treated mice
impaired coordination ( J:328215 )
• on a rotarod at three months in tamoxifen-treated mice
seizures ( J:328215 )
• in some tamoxifen-treated mice

endocrine/exocrine glands
small testis ( J:328215 )
• after 35 days of tamoxifen treatment
decreased testis weight ( J:328215 )
• after 35 days of tamoxifen treatment
testis degeneration ( J:328215 )
• with partial collapse of seminiferous tubules and defective germ line maturation in tamoxifen-treated mice

growth/size/body
decreased body weight ( J:328215 )
• reduced weight gain for 70 days following tamoxifen treatment with mice never catching up to wild-type mice
enlarged liver ( J:328215 )
• after 40-50 days of tamoxifen treatment

homeostasis/metabolism
increased circulating cholesterol level ( J:328215 )
• after 43 days of tamoxifen treatment

liver/biliary system
enlarged liver ( J:328215 )
• after 40-50 days of tamoxifen treatment
liver inflammation ( J:328215 )
• with ballooning degeneration in the parenchyma and occasional foci of lymphocytic infiltration in tamoxifen-treated mice
abnormal hepatocyte morphology ( J:328215 )
• enlarged in tamoxifen-treated mice
increased hepatocyte karyomegaly ( J:328215 )
• in tamoxifen-treated mice

immune system
liver inflammation ( J:328215 )
• with ballooning degeneration in the parenchyma and occasional foci of lymphocytic infiltration in tamoxifen-treated mice

nervous system
seizures ( J:328215 )
• in some tamoxifen-treated mice

cellular
increased hepatocyte karyomegaly ( J:328215 )
• in tamoxifen-treated mice




Genotype
MGI:7612206
cn20
Allelic
Composition		 Armcx3tm1.1Eso/Y
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Armcx3tm1.1Eso mutation (1 available); any Armcx3 mutation (5 available)
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
growth/size/body
decreased susceptibility to diet-induced obesity ( J:345411 )
• tamoxifen-treated mice fed a high-fat diet gain less body weight than controls
• tamoxifen-treated mice injected with DEN exhibit a lower increase in body weight compared to DEN-injected controls, regardless of diet; this is due to reduced adiposity and not growth

liver/biliary system
decreased susceptibility to diet-induced hepatic steatosis ( J:345411 )
• tamoxifen-treated mice are resistant to developing high-fat diet induced non-alcohol fatty liver disease
• tamoxifen-treated mice, injected with DEN and fed a high-fat diet show strongly reduced hepatic steatosis

neoplasm
decreased incidence of tumors by chemical induction ( J:345411 )
• mice treated with tamoxifen on days 1 to 3 after birth then injected with diethylnitrosamine (DEN) 14 days later to induce hepatic carcinogenesis and fed a high-fat diet show a decrease in liver tumor number, average tumor size and maximum tumor size compared with controls, indicating decreased susceptibility to DEN-induced tumorigenesis on a high-fat diet
• tumor regions show increased hepatocyte apoptosis and a greater accumulation of macrophages than in controls
abnormal tumor morphology ( J:345411 )
• a greater accumulation of macrophages is seen in tumors from high-diet fed, DEN-injected, and tamoxifen-treated mutants than in controls
• tumor regions, but not non-tumor regions, from tamoxifen-treated, DEN-injected, and high-fat diet fed mice show increased hepatocyte apoptosis

homeostasis/metabolism
decreased susceptibility to diet-induced obesity ( J:345411 )
• tamoxifen-treated mice fed a high-fat diet gain less body weight than controls
• tamoxifen-treated mice injected with DEN exhibit a lower increase in body weight compared to DEN-injected controls, regardless of diet; this is due to reduced adiposity and not growth
decreased circulating glucose level ( J:345411 )
• tamoxifen-treated mice, injected with DEN and fed a low-fat diet show lower glycemia than controls
increased circulating insulin level ( J:345411 )
• tamoxifen-treated mice fed a low-fat diet exhibit higher insulin levels
decreased circulating alanine transaminase level ( J:345411 )
• tamoxifen-treated mice fed a high-fat diet show a reduction in alanine aminotransferase (ALT) activity in plasma compared to controls, indicating reduced hepatocellular injury
• tamoxifen-treated mice, injected with DEN and fed a high-fat diet show blunted ALT activity
improved glucose tolerance ( J:345411 )
• tamoxifen-treated mice fed a high-fat diet exhibit improved glucose tolerance
increased insulin sensitivity ( J:345411 )
• the HOMA-IR index is blunted in tamoxifen-treated mice fed a high-fat diet compared to an increase in controls
decreased incidence of tumors by chemical induction ( J:345411 )
• mice treated with tamoxifen on days 1 to 3 after birth then injected with diethylnitrosamine (DEN) 14 days later to induce hepatic carcinogenesis and fed a high-fat diet show a decrease in liver tumor number, average tumor size and maximum tumor size compared with controls, indicating decreased susceptibility to DEN-induced tumorigenesis on a high-fat diet
• tumor regions show increased hepatocyte apoptosis and a greater accumulation of macrophages than in controls

behavior/neurological
increased food intake ( J:345411 )
• tamoxifen-treated mice fed a high-fat diet have a higher food intake than controls

adipose tissue
decreased total body fat amount ( J:345411 )
• tamoxifen-treated mice injected with DEN show reduced adiposity, as seen by smaller adipose depots, regardless of diet




Genotype
MGI:6276274
cn21
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3+
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/6N
Cell Lines EPD0441_1_B10
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rnpc3tm1c(EUCOMM)Wtsi mutation (0 available); any Rnpc3 mutation (41 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:267519 )
• tamoxifen-treated adult mice appear phenotypically normal with no significant weight loss relative to control mice




Genotype
MGI:6276277
cn22
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3tm1c(EUCOMM)Wtsi
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/6N
Cell Lines EPD0441_1_B10
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Rnpc3tm1c(EUCOMM)Wtsi mutation (0 available); any Rnpc3 mutation (41 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
moribund ( J:267519 )
• at 8 days after tamoxifen (TAM) treatment, adult mice show signs of malnutrition and stress (scruffy coat, docile, and hunched behavior) requiring euthanasia

growth/size/body
weight loss ( J:267519 )
• adult mice show irreversible weight loss by 6 days after TAM treatment

behavior/neurological
hunched posture ( J:267519 )
• hunched behavior at 8 days after TAM treatment

immune system
small intestinal inflammation ( J:267519 )
• infiltration of immune cells in small intestinal epithelium at 6 days after TAM treatment
esophageal inflammation ( J:267519 )
• signs of erosive esophagitis at 8 days after TAM treatment
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
decreased leukocyte cell number ( J:267519 )
• significant leucopenia at 8 days after TAM treatment
decreased lymphocyte cell number ( J:267519 )
• significant decrease in lymphocyte number at 8 days after TAM treatment
decreased monocyte cell number ( J:267519 )
• significant decrease in monocyte number at 8 days after TAM treatment

digestive/alimentary system
increased small intestinal crypt cell apoptosis ( J:267519 )
• significant increase in the number of apoptotic cells in the highly proliferative, stem/progenitor compartment of the small intestinal crypts at 2 and 4 days after TAM treatment
abnormal enterocyte proliferation ( J:267519 )
• reduced cell proliferation in the proliferative compartment of the small intestinal epithelium at 4 days after TAM treatment
abnormal small intestinal crypt cell proliferation ( J:267519 )
• marked reduction in BrdU+ cells in small intestinal crypts at 4 days after TAM treatment
• new BrdU+ crypt-like structures corresponding to sites of regeneration at 6 and 8 days after TAM treatment
abnormal digestive system morphology ( J:267519 )
• severe atrophy of the entire gastrointestinal epithelium with mucosa disruption from the esophagus to the rectum at 8 days after TAM treatment
• extensive degeneration of the epithelial layer interspersed with discrete pockets of regenerating crypt-like structures
abnormal esophageal squamous epithelium morphology ( J:267519 )
• disrupted organization of the squamous epithelium of the esophagus at 8 days after TAM treatment
abnormal intestinal epithelium morphology ( J:267519 )
• at 8 days after TAM treatment, the epithelial monolayer lining the small intestine and colon contains vacuolated epithelial cells scattered throughout the submucosa; epithelial layer degeneration is intermixed with discrete pockets of regenerating crypt-like structures
• loss of epithelial integrity in the small intestine and colon with nuclei rounding up and cells losing apico-basal polarity at 4 days after TAM treatment
• highly disorganized small intestine epithelium, with crypt loss, decreased villus height, infiltration of immune cells, and ulceration at 6 days after TAM treatment
• thinner and flatter epithelial cells in the colon at 6 days after TAM treatment
abnormal intestinal mucosa morphology ( J:267519 )
• at 8 days after TAM treatment
abnormal large intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the colon at 4 days after TAM treatment
• large vacuolated spaces in colonic crypts at 6 days after TAM treatment
abnormal small intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the small intestine at 4 days after TAM treatment
decreased small intestinal villus height ( J:267519 )
• reduced villus height in the small intestine at 6 days after TAM treatment
abnormal stomach glandular epithelium morphology ( J:267519 )
• degeneration of columnar mucous epithelium of the glandular stomach at 8 days after TAM treatment
small intestinal inflammation ( J:267519 )
• infiltration of immune cells in small intestinal epithelium at 6 days after TAM treatment
esophageal inflammation ( J:267519 )
• signs of erosive esophagitis at 8 days after TAM treatment

hematopoietic system
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
anemia ( J:267519 )
• significant anemia at 8 days after TAM treatment
decreased erythrocyte cell number ( J:267519 )
• significant decrease in RBC number at 8 days after TAM treatment
thrombocytopenia ( J:267519 )
• severe thrombocytopenia at 8 days after TAM treatment
decreased leukocyte cell number ( J:267519 )
• significant leucopenia at 8 days after TAM treatment
decreased lymphocyte cell number ( J:267519 )
• significant decrease in lymphocyte number at 8 days after TAM treatment
decreased monocyte cell number ( J:267519 )
• significant decrease in monocyte number at 8 days after TAM treatment

integument
sebaceous gland atrophy ( J:267519 )
• paucity of sebaceous glands at 8 days after TAM treatment
disheveled coat ( J:267519 )
• scruffy coat at 8 days at 8 days after TAM treatment
abnormal skin morphology ( J:267519 )
• mild skin abnormalities at 8 days after TAM treatment
epidermal atrophy ( J:267519 )
• attenuated epidermis at 8 days after TAM treatment

endocrine/exocrine glands
abnormal large intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the colon at 4 days after TAM treatment
• large vacuolated spaces in colonic crypts at 6 days after TAM treatment
abnormal small intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the small intestine at 4 days after TAM treatment
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
sebaceous gland atrophy ( J:267519 )
• paucity of sebaceous glands at 8 days after TAM treatment

cellular
increased small intestinal crypt cell apoptosis ( J:267519 )
• significant increase in the number of apoptotic cells in the highly proliferative, stem/progenitor compartment of the small intestinal crypts at 2 and 4 days after TAM treatment
abnormal enterocyte proliferation ( J:267519 )
• reduced cell proliferation in the proliferative compartment of the small intestinal epithelium at 4 days after TAM treatment
abnormal small intestinal crypt cell proliferation ( J:267519 )
• marked reduction in BrdU+ cells in small intestinal crypts at 4 days after TAM treatment
• new BrdU+ crypt-like structures corresponding to sites of regeneration at 6 and 8 days after TAM treatment




Genotype
MGI:6403623
cx23
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Trp53tm1Brd/Trp53tm1Brd
Genetic
Background		 involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (11 available); any Ndor1 mutation (30 available)
Trp53tm1Brd mutation (5 available); any Trp53 mutation (249 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
tumor regression ( J:223417 )
• in tamoxifen treated mice compared with untreated mice due to increased apoptosis in tumor cells




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
03/18/2025
MGI 6.24 		The Jackson Laboratory